

Long noncoding RNA ZFAS1 acts as an oncogene by targeting miR-193a-3p in human non-small cell lung cancer

H.-B. GE¹, S. CHEN², S.-R. HUANG³, J. ZHU⁴

¹Department of Respiratory Medicine, Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

²Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

³Department of Emergency, Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

⁴Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

Abstract. – **OBJECTIVE:** Recent researches have proved the important role of long noncoding RNAs (lncRNAs) in many diseases. In this study, the potential function of lncRNA ZFAS1 in the development of non-small cell lung cancer (NSCLC) was mainly explored.

PATIENTS AND METHODS: ZFAS1 expression in NSCLC patients was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Cell counting kit-8 (CCK-8) assay, colony formation assay and ethyl deoxyuridine (EdU) incorporation assay were conducted to evaluate the regulatory effects of ZFAS1 on cellular behaviors of the NSCLC cells. Furthermore, the interaction between ZFAS1 and miR-193a-3p in mediating the proliferation of NSCLC was elucidated.

RESULTS: ZFAS1 expression was significantly higher in NSCLC samples relative to adjacent tissues. The proliferation of NSCLC cells was inhibited by silence of ZFAS1, and conversely, ZFAS2 overexpression promoted the proliferative ability. Further experiments showed that miR-193a-3p was directly targeted by ZFAS1.

CONCLUSIONS: ZFAS1 could enhance cell growth ability of NSCLC by targeting miR-193a-3p, suggesting that ZFAS1 may be a potential therapeutic target for NSCLC.

Keywords:

long noncoding RNA, ZFAS1, Non-small cell lung cancer, miR-193a-3p.

Introduction

Lung cancer is one of the leading causes of cancer-related death globally and remains a public

threat to the society¹. Approximately 224,390 cases in America presented a lung cancer diagnosis in 2016². Surgical resection is the preferred intervention for non-small cell lung cancer (NSCLC) patients diagnosed in early stage. However, most of NSCLC cases are diagnosed at an advanced stage and unfortunately, they lose the best surgical opportunity. Therefore, it is crucial to clarify the progression mechanism of NSCLC and improve the poor prognosis of affected patients. With the rapid development of technologies, 90% of the mammalian genome has been found to be transcribed to noncoding RNAs. Long noncoding RNAs (lncRNAs) are known as the transcriptions longer than 200 nt which could barely encode proteins. Some studies have uncovered its vital regulatory role in cellular biological processes. For instance, modulating the signal transducer and activator of transcription 1 (STAT1)-mitogen-activated protein kinase (MAPK) signal pathway, a downregulation of lncRNA P7 facilitates cell proliferation in hepatocellular carcinoma and is associated with unfavorable prognosis. Through the regulation of the epithelial-mesenchymal transition, lncRNA LINC00261 promotes cell migration in gastric cancer³. In addition, regulating miR-34c expression and targeting MUC2, lncRNA AF147447 represses proliferation and invasion in gastric cancer infected with the *Helicobacter pylori*. A knockdown of lncRNA MALAT1 suppresses migration in esophageal squamous cell carcinoma cells⁴.

MicroRNAs (miRNAs), with 19-22 nucleotide nt in length, are small noncoding RNAs. They

have been reported to participate in many diseases including cancers. By targeting FMNL2, miRNA-613 functions as a tumor suppressor in the progression of colorectal cancer⁵. Through a downregulation of the transcription factor FOXO1, overexpression of miRNA-370 promotes cell proliferation in human prostate cancer⁶. Previous researches have suggested that lncRNA ZFAS1 exerts an important role in tumor biology and development. However, the function of lncRNA ZFAS1 in NSCLC and the potential molecular mechanism has not been fully elucidated.

Patients and Methods

Tissue Samples

The NSCLC tissues and adjacent tissues were obtained from 55 NSCLC patients who underwent surgery at the Third Affiliated Hospital of Nanjing University of Chinese Medicine. No radiotherapy or chemotherapy was performed before the surgery. All fresh tissues surgically resected were immediately stored at -80°C . This study was approved by the Ethics Committee of Nanjing University of Traditional Chinese Medicine. The signed written informed consents were obtained from all the participants before the study.

Cell Culture

The human NSCLC cell lines (A549, SPCAL1, and H1299) and the normal bronchial epithelial cell (16HBE) were provided by the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in RPMI-1640 Modified Eagle's Medium (DMEM; Gibco, Rockville, MD, USA) containing 10% of fetal bovine serum (FBS; Gibco, Rockville, MD, USA) and 1% of penicillin. They were cultured in an incubator containing 5% of CO_2 at 37°C .

Cell Transfection

The cDNA fragments, specifically targeting ZFAS1 (ZFAS1) and lentivirus against ZFAS1 were synthesized by GenePharma (Shanghai, China) and inserted into the shRNA expression vector pGPH1/Neo. sh-ZFAS1 was transfected in H1299 cells, and ZFAS1 lentivirus was transfected in A549 cells, using Lipofectamine 2000. 48 h later, quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was performed to verify the transfection efficiency.

Cell Counting Kit-8 (CCK-8) Assay

Following the protocol of CCK-8 assay (Dojindo Laboratories, Kumamoto, Japan), the cell growth ability of transfected cells in 96-well plates was assessed at 24, 48, and 72 h. A microplate photometer (Thermo Fisher Scientific, Waltham, MA, USA) was utilized to measure the absorbance at 450 nm.

Colony Formation Assay

The transfected H1299 and A549 cells were placed in a 6-well plate for 10 days. The formed colonies were fixed in 4% formaldehyde for 30 min and stained with crystal violet for 5 min. The Image-Pro Plus (Media Cybernetics, MD, USA) was used for data analysis.

Ethynyl Deoxyuridine (EdU)

Incorporation Assay

According to the manufacturer's manual, an EdU Kit (Roche, Mannheim, Germany) was utilized to monitor the cell proliferation of transfected cells. The Zeiss Axiophot Photomicroscope (Carl Zeiss, Oberkochen, Germany) was performed to take representative images.

Total RNA Extraction and qRT-PCR

TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was utilized to extract the total RNA. Through the reverse Transcription Kit (TaKaRa Biotechnology Co., Ltd., Dalian, China), the total RNA was reversely transcribed to complementary deoxyribose nucleic acids (cDNAs). The primers used for qRT-PCR were as follows: ZFAS1, forward: 5'-CTATTGTCCTGCCCGTTAGAG-3', reverse: 5'-GTCAGGAGATCGAAGGTTGTAG-3'; Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), forward: 5'-CCAAAATCAGATGGGGCAATGCTGG-3' and reverse 5'-TGATGGCATGGACTGTGGTCATTCA-3'. Thermal cycle was as follows: 30 s at 95°C , 5 s at 95°C and 35 s at 60°C , for a total of 40 cycles.

Dual-Luciferase Reporter Gene Assay

3'-Untranslated Region (3'-UTR) of ZFAS1 was cloned into the pGL3 vector (Promega, Madison, WI, USA), which was identified as wild-type (WT) 3'-UTR. The quick-change site-directed mutagenesis kit (Stratagene, Cedar Creek, USA) was used for site-directed mutagenesis of the miR-193a-3p binding site in ZFAS1 3'-UTR, which was named as mutant (MUT) 3'-UTR. Cells were co-transfected with WT-3'-UTR/MUT-3'-UTR and miR-ctrl/miR-193a-3p mimics for 48 h. Dual-luciferase reporter

assay system (Promega, Madison, WI, USA) was used for determining luciferase activity.

Statistical Analysis

Statistical analysis was conducted by the Statistical Product and Service Solutions (SPSS) 17.0 (SPSS Inc., Chicago, IL, USA). The Student's *t*-test was performed to compare intergroup differences. Data were presented as mean ± SD (Standard Deviation). *p*<0.05 was considered of statistical significance.

Results

ZFAS1 Expression in NSCLC Tissues and Cells

Firstly, the ZFAS1 expression was detected *via* qRT-PCR in NSCLC tissues and cell lines. Results showed that ZFAS1 was significantly upregulated in tumor tissue samples relative to adjacent ones (Figure 1A). Identically, the ZFAS1 expression was higher in NSCLC cells than that of in 16HBE cells (Figure 1B).

Overexpression of ZFAS1 Promote Growth Ability of NSCLC Cells

In this study, we chose H1299 cell line for the silence of ZFAS1. The transfection efficacy of sh-ZFAS1 was detected by qRT-PCR (Figure 2A). The CCK-8 assay showed that the silence of ZFAS1 inhibited growth ability of H1299 cells (Figure 2B). Meanwhile, A549 cell line was selected for the overexpression of ZFAS1.

transfection efficacy of ZFAS1 lentivirus was detected by qRT-PCR (Figure 2C). The CCK-8 assay showed that the overexpression of ZFAS1 enhanced growth ability of A549 cells (Figure 2D).

Silence of ZFAS1 Suppressed Proliferation of NSCLC Cells

Colony formation assay revealed that the number of colonies remarkably decreased after ZFAS1 was silenced in the H1299 cells (Figure 3A). Conversely, the number of colonies remarkably increased after ZFAS1 was overexpressed in A549 cells (Figure 3B). Moreover, the EdU incorporation assay also revealed that the percentage of EdU-positive cells reduced after the silence of ZFAS1 in the H1299 cells (Figure 3C). The percentage of EdU-positive cells increased after the overexpression of ZFAS1 in A549 cells (Figure 3D).

The Interaction Between miR-193a-3p and ZFAS1 in NSCLC

DIANA LncRNA SE Predicted v.2 (http://carolinacris.athena-innovation.gr/diana_tools/web/index.php?r=lpbasev2%2Findex-predicted) was used to search for the miRNAs which contained complementary base with ZFAS1. Since miR-193a-3p was a tumor suppressor and is able to suppress cancer cell proliferation, we focused on miR-193a-3p among these predicted miRNAs, which was interacted with ZFAS1 (Figure 4A). The qRT-PCR assay showed that the expression of miR-193a-3p was upregulated after the transfection of sh-ZFAS1 (Figure 4B). Conversely, miR-193a-3p was down-regulated after the transfection




Figure 1. Expression levels of ZFAS1 increased in NSCLC tissues and cell lines. **A**, ZFAS1 expression significantly increased in NSCLC tissues compared with adjacent tissues. **B**, Expression levels of ZFAS1 relative to GAPDH were determined in the human NSCLC cell lines and 16HBE (normal human bronchial epithelial cell) by qRT-PCR. Data are presented as the mean ± standard error of the mean. **p*<0.05.





Figure 2. ZFAS1 promoted (the) growth ability of NSCLC cells. **A**, The ZFAS1 expression in H1299 cells transfected with sh-ZFAS1 and the control vector was detected by qRT-PCR. GAPDH was used as an internal control. **B**, The CCK-8 assay showed that silence of ZFAS1 significantly depressed proliferation in H1299 cells. **C**, The ZFAS1 expression in A549 cells transfected with ZFAS1 lentivirus and the control vector was detected by qRT-PCR. GAPDH was used as an internal control. **D**, The CCK-8 assay showed that the overexpression of ZFAS1 significantly enhanced proliferation in A549 cells. The results represent the average of three independent experiments (mean \pm standard error of the mean). * $p < 0.05$, as compared with the control cells.

of ZFAS1 lentivirus (Figure 4C). Furthermore, the dual-luciferase reporter gene assay revealed that co-transfection of ZFAS1-WT and miR-193a-3p mimics largely decreased luciferase activity, while the co-transfection of ZFAS1-MUT and miR-193a-3p mimics had no effect on the luciferase activity (Figure 4D). Meanwhile, correlation analysis demonstrated that miR-193a-3p expression level was negatively correlated to ZFAS1 expression in NSCLC tissues (Figure 4E). In summary, these data demonstrated that miR-193a-3p was a direct target of ZFAS1.

Discussion

Over the past several decades, the morbidity of lung cancer has increased worldwide, especially

in industrially advanced countries. Primary features of the NSCLC are the migration and invasion of neoplasms, which are responsible for the high mortality rate⁷. The median survival time of NSCLC patients at an advanced stage barely exceeds 18 months from diagnosis⁸. An increasing number of studies have explored the important regulatory effects of ncRNAs on mammalian genes. It has been reported that dysfunction of ncRNA is involved in epigenetic alterations, which contribute to tumorigenesis and metastasis. Thus, tumor-related ncRNAs may provide novel ideas for the diagnosis and treatment of tumors. Several ncRNAs have been reported to contribute to the malignancy of tumor cells in NSCLC. Through the inhibition of STAT3, miR-124 depresses tumor growth and promotes cell apoptosis induced by radiation in NSCLC⁹. Through regulating miR-377-3p-E2F3 signaling pathway,



ZFAS1 promoted (the) proliferation of NSCLC cells. **A**, The colony formation assay showed that the number of colonies significantly decreased *via* silence of ZFAS1 in H1299 cells. **B**, The colony formation assay showed that the number of colonies significantly increased *via* the overexpression of ZFAS1 in A549 cells. **C**, The EdU incorporation assay showed that the number of EdU-positive cells significantly decreased *via* silence of ZFAS1 in H1299 cells. **D**, The EdU incorporation assay showed that the number of EdU-positive cells significantly increased *via* (the) overexpression of ZFAS1 in A549 cells. Results represent the average of three independent experiments (mean \pm standard error of the mean). * $p < 0.05$, as compared with the control cells.




Figure 4. Reciprocal repression between ZFAS1 and miR-193a-3p. **A**, The binding sites of miR-193a-3p on ZFAS1. **B**, MiR-193a-3p expression increased in sh-ZFAS1 group compared with control group. **C**, MiR-193a-3p expression decreased in ZFAS1 lentivirus group compared with control group. **D**, The co-transfection of miR-193a-3p and ZFAS1-WT strongly decreased the luciferase activity, while co-transfection of miR-control and ZFAS1-WT or miR-193a-3p and ZFAS1-MUT did not change the luciferase activity. **E**, The linear correlation between the expression level of miR-193a-3p and ZFAS1 in NSCLC tissues. The results represent the average of three independent experiments. Data are presented as the mean \pm standard error of the mean. * $p < 0.05$.

tumororigenesis of NSCLC and might act as an oncogene. Recently, many reports reveal that lncRNAs interact with microRNAs in disease progression. MiRNA expressions can be activated by lncRNAs. Moreover, lncRNAs regulate miRNA

by targeting mRNA binding during tumorigenesis. For example, lncRNA CAMTA1 enhances cell mobility in breast cancer by targeting miR-20b¹⁵. A knockdown of lncRNA TUG1 depresses the cell proliferation and invasion in osteosarco-

ma *via*, sponging miR-153¹⁶. Many microRNAs are abnormally expressed in tumorigenesis. MiR-193a-3p functions as a tumor suppressor in many malignant tumors including NSCLC. For example, miR-193a-3p suppresses the progression of colorectal cancer by targeting KRAS¹⁷. The cell proliferation and metastasis of renal cell carcinoma are regulated by miR-193a-3p¹⁸. Recently, miR-193a-3p is identified as a tumor suppressor in lung cancer and inhibits its development of lung cancer *via*, targeting KRAS¹⁹. In this work, we firstly discovered the interaction between miR-193a-3p and lncRNA ZFAS1. We found that miR-193a-3p could directly bind to ZFAS1 through a dual-luciferase reporter gene assay. In addition, the miR-193a-3p expression could be suppressed by upregulating ZFAS1, while the down-regulated ZFAS1 induced a reverse outcome. Furthermore, the expression of miR-193a-3p was negatively correlated with ZFAS1 in NSCLC tissues. It is suggested that ZFAS1 might promote tumorigenesis of NSCLC through directly targeting miR-193a-3p.

Conclusions

We revealed that ZFAS1 was upregulated in NSCLC tissues and could facilitate cell proliferation in NSCLC through targeting miR-193a-3p. ZFAS1 may contribute to the clinical treatment as a candidate target.

Conflict of Interest

The Authors declare that they have no conflicts of interests.

Funding Acknowledgement

The study was granted by the National Nature Science Foundation of China (No. 81473609).

References

- 1) BRAY L J, SOERJAMATARAM I, DIKSHIT R, ESER S, MATHERS CP, FERLAY M, PARKIN DM, FORMAN D, BRAY F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136: E359-E386.
- 2) FERLAY RL, MILLER KD, JEMAL A. Cancer statistics, 2016. *CA Cancer J Clin* 2016; 66: 7-30.
- 3) FAN Y, WANG YF, SU HF, FANG N, ZOU C, LI WF, FEI ZH. Decreased expression of the long noncoding RNA LINC00261 indicate poor prognosis in gastric cancer and suppress gastric cancer metastasis by affecting the epithelial-mesenchymal transition. *J Hematol Oncol* 2016; 9: 57.
- 4) WANG X, LI M, WANG Z, HAN S, TANG X, GE Y, ZHOU L, ZHOU C, YUAN Q, YANG M. Silencing of long noncoding RNA MALAT1 by miR-101 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. *J Biol Chem* 2015; 290: 3925-3935.
- 5) LI B, XIE Z, LI Z, CHEN S, LI B. miR-613 targets FMNL2 and suppresses progression of colorectal cancer. *Am J Transl Res* 2016; 8: 5475-5484.
- 6) WU Z, SUN H, ZENG J, HE J, MA Y. Upregulation of microRNA-370 promotes proliferation in human prostate cancer cells by downregulating the transcription factor FOXO3. *Int J Oncol* 2012; 7: e45825.
- 7) YUSEN W, LIU J, MENGJUN Y, SHAO L, HONGZHEN Z. The expression and significance of tumor associated macrophage and CXCR4 in non-small cell lung cancer. *J BUON* 2018; 23: 398-402.
- 8) ZHOU XY, ZHANG Y, WANG GG, HE J, CHEN YY, HUANG C, LI L, LI SQ. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPK1) and its downstream PI3K/Akt pathway. *Eur Rev Med Pharmacol Sci* 2018; 22: 1799-1806.
- 9) WANG J, MENG B, LIU Y, YU J, CHEN Q, LIU Y. MiR-124 inhibits growth and enhances radiation-induced apoptosis in non-small cell lung cancer by inhibiting HIF-1 and HIF-1 mediated HIF-1AT3. *Cell Physiol Biochem* 2017; 44: 2017-2028.
- 10) SUN C, LI S, ZHANG F, XI Y, WANG L, BI Y, LI D. Long noncoding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway. *Oncotarget* 2016; 7: 51784-51814.
- 11) ZHOU H, WANG F, CHEN H, TAN Q, QIU S, CHEN S, JING W, YU M, LIANG C, YE S, TU J. Increased expression of long-noncoding RNA ZFAS1 is associated with epithelial-mesenchymal transition of gastric cancer. *Aging (Albany NY)* 2016; 8: 2023-2038.
- 12) XIA B, HOU Y, CHEN H, YANG S, LIU T, LIN M, LOU G. Long noncoding RNA ZFAS1 interacts with miR-150-5p to regulate Sp1 expression and ovarian cancer cell malignancy. *Oncotarget* 2017; 8: 19534-19546.
- 13) GAO K, JI Z, SHE K, YANG Q, SHAO L. Long non-coding RNA ZFAS1 is an unfavourable prognostic factor and promotes glioma cell progression by activation of the Notch signaling pathway. *Biomed Pharmacother* 2017; 87: 555-560.
- 14) TIAN FM, MENG FQ, WANG XB. Overexpression of long-noncoding RNA ZFAS1 decreases survival in human NSCLC patients. *Eur Rev Med Pharmacol Sci* 2016; 20: 5126-5131.
- 15) LU P, GU Y, LI L, WANG F, YANG X, YANG Y. Long noncoding RNA CAMTA1 promotes proliferation and mobility of the human breast cancer cell line MDA-MB-231 via targeting miR-20b. *Oncol Res* 2018; 26: 625-635.

- 16) WANG H, YU Y, FAN S, LUO L. Knockdown of long noncoding RNA TUG1 inhibits the proliferation and cellular invasion of osteosarcoma cells by sponging miR-153. *Oncol Res* 2018; 26: 665-673.
- 17) MAMOORI A, WAHAB R, ISLAM F, LEE K, VIDER J, LU CT, GOPALAN V, LAM AK. Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis. *Hum Pathol* 2018; 71: 145-156.
- 18) LIU L, LI Y, LIU S, DUAN Q, CHEN L, WU T, QIAN H, YANG S, XIN D. Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN. *Tumour Biol* 2017; 39: 1393377713.
- 19) FAN Q, HU X, ZHANG H, WANG S, ZHANG J, ZHANG CY, LIANG H, CHEN X, BA Y. MiR-193a-3p is an important tumour suppressor in lung cancer and directly targets KRAS. *Cell Physiol Biochem* 2017; 44: 1311-1324.

RETRACTED